Glutamatergic agents for schizophrenia: Current evidence and perspectives

Expert Review of Clinical Pharmacology

Volumn 8, Issue 3, 2015, Pages 335-352

  Zink, Mathias ^a   Correll, Christoph U ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

Author keywords

amino acid neurotransmission; antipsychotic; cognition; glutamate; psychosis; schizophrenia

Indexed keywords

BIOLOGICAL MARKER; CLOZAPINE; DOPAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; GLYCINE; LAMOTRIGINE; METABOTROPIC RECEPTOR AGONIST; MOOD STABILIZER; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT; PLACEBO; TOPIRAMATE; AMINO ACID RECEPTOR AFFECTING AGENT; GLUTAMIC ACID;

AMINO ACID NEUROTRANSMISSION; BINDING SITE; BRAIN DEVELOPMENT; BRAIN MATURATION; CLINICAL RESEARCH; COGNITION; COGNITIVE DEFECT; COGNITIVE THERAPY; DOPAMINE BRAIN LEVEL; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; DOSE RESPONSE; DRUG TREATMENT FAILURE; GINKGO BILOBA; HEALTH CARE UTILIZATION; HUMAN; MEDICATION COMPLIANCE; MENTAL HEALTH; MONOTHERAPY; NEGATIVE SYNDROME; NEUROLOGIC DISEASE; NEUROTRANSMISSION; NONHUMAN; POSITIVE SYNDROME; PRESCRIPTION; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; TREATMENT OUTCOME; ANIMAL; COGNITION DISORDERS; METABOLISM; PATHOPHYSIOLOGY; PATIENT SELECTION; PSYCHOLOGY;

ANIMALS; ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID AGENTS; GLUTAMIC ACID; HUMANS; PATIENT SELECTION; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 84928647586     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2015.1040393     Document Type: Review

References (201)

1. van Os J, Kapur S. Schizophrenia. Lancet 2009;374(9690):635-45
2. Collaborators GMaCoD. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013. The Lancet 2015;385(9963):117-71
3. Zink M, Englisch S, Meyer-Lindenberg A. Polypharmacy in schizophrenia. Curr Opin Psychiatry 2010;23(2):103-11
4. Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry 2012;14(1):2-44
5. Jääskeläinen E, Juola P, Hirvonen N, et al. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull 2013;39:1296-306
6. Angermeyer MC, Matschinger H, Schomerus G. Attitudes towards psychiatric treatment and people with mental illness: changes over two decades. Br J Psychiatry 2013;203:146-51
7. Gerlinger G, Hauser M, De Hert M, et al. Personal stigma in schizophrenia spectrum disorders: A systematic review of prevalence rates, correlates, impact and interventions. World Psychiatry 2013;12(2):155-64
8. Howes OD, Kambeitz J, Kim E, et al. The Nature of dopamine dysfunction in schizophrenia and what this means for treatment: A meta-analysis of imaging studies. Arch Gen Psychiatry 2012;69(8): 776-86
9. Kantrowitz J, Javitt DC. Glutamatergic transmission in schizophrenia: from basic research to clinical practice. Curr Opin Psychiatry 2013;25(2):96-102
10. Correll CU. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry 2010; 25(Suppl 2):S12-21
11. Kane JM, Correll CU. Past and Present Progress in the Pharmacologic Treatment of Schizophrenia. J Clin Psychiatry 2010;71(9): 1115-24
12. Carbon M, Correll CU. Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia. CNS Spectr 2014; 19(Suppl S1):35-53
13. Meltzer HY. An overview of the mechanism of action of clozapine. J Clin Psychiatry 1994;55(Suppl B):47-52
14. Daskalakis ZJ, George TP. Clozapine, GABA(B), and the treatment of resistant schizophrenia. Clin Pharmacol Ther 2009; 86(4):442-6
15. Tanahashi S, Yamamura S, Nakagawa M, et al. Clozapine, but not haloperidol, enhances glial d-serine and L-glutamate release in rat frontal cortex and primary cultured astrocytes. Br J Pharmacol 2012; 165(5):1543-55
16. Schirmbeck F, Zink M. Comorbid obsessive-compulsive symptoms in schizophrenia: contributions of pharmacological and genetic factors. Front Pharmacol 2013;4:99
17. Correll CU. What are we looking for in new Antipsychotics? J Clin Psychiatry 2011; 72(Suppl 1):9-13
18. Miyamoto S, Miyake N, Jarskog LF, et al. Pharmacological treatment of schizophrenia: A critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry 2012; 17(12):1206-27
19. Koester LS, Carbon M, Correll CU. Emerging drugs for schizophrenia: An update. Expert Opi Emerg Drugs 2014; 19(4):511-31
20. Gupta S, Cahill JD, Ranganathan M, Correll CU. The endocannabinoid system and schizophrenia: links to the underlying pathophysiology and to novel treatment approaches. J Clini Psychiatry 2014;75(3): 285-7
21. Jauhar S, McKenna PJ, Radua J, et al. Cognitive-behavioural therapy for the symptoms of schizophrenia: systematic review and meta-analysis with examination of potential bias. Br J Psychiatry 2014; 204(1):20-9
22. Sarin F, Wallin L, Widerloev B. Cognitive behavior therapy for schizophrenia: A meta-analytical review of randomized controlled trials. Nord J Psychiatry 2011; 65(3):162-74
23. Schirmbeck F, Zink M. Cognitive-behavioural therapy for obsessive-compulsive symptoms in schizophrenia. The Cognitive Behavioural Therapist 2013;6:e7
24. Grant PM, Huh GA, Perivoliotis D, et al. Randomized trial to evaluate the efficacy of cognitive therapy for low-functioning patients with schizophrenia. Arch Gen Psychiatry 2012;69(2):121-7
25. Gaebel W, Riesbeck M, Wobrock T. Schizophrenia guidelines across the world: A selective review and comparison. Int Rev Psychiatry 2011;23(4):379-87
26. Naeem F, Farooq S, Kingdom D. Cognitive behavioural therapy (brief versus standard duration) for schizophrenia. Cochrane Database Syst Rev 2014;4:CD010646
27. Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry 2013;12(3): 216-26
28. Correll CU. Recognition of patients who would benefit from LAI antipsychotic treatment: how to assess adherence. J Clin Psychiatry 2014;75:11
29. Kane JM, Kishimoto T, Correll CU. Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry. J Clin Epidemiol 2013;66(8 Suppl):S37-41
30. Kishimoto T, Robenzadeh A, Leucht C, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: A meta-analysis of randomized trials. Schizophr Bull 2014; 40(1):192-213
31. McEvoy JP, Byerly M, Hamer RM, et al. Effectiveness of Paliperidone Palmitate vs Haloperidol Decanoate for Maintenance Treatment of Schizophrenia A Randomized Clinical Trial. JAMA 2014;311(19):1978-87
32. Nielsen J, Jensen SO, Friis RB, et al. Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study. Schizophr Bull 2015;41(3):627-36
33. Kishimoto T, Nitta M, Borenstein M, et al. Long-acting injectable versus oral antipsychotics in schizophrenia: A systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry 2013;74(10): 957-65
34. Kang X, Simpson GM. Clozapine: more side effects but still the best antipsychotic. J Clin Psychiatry 2010;71(8):982-3
35. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45(9):789-96
36. McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. see comment Am J Psychiatry 2006;163(4):600-10
37. Still DJ, Dorson PG, Crismon ML, Pousson C. Effects of switching inpatients with treatment-resistant schizophrenia from clozapine to risperidone. Psychiatric Services 1996;47(12):1382-4
38. Gupta S, Daniel DG. Cautions in the clozapine-to-risperidone switch. Ann Clin Psychiatry 1995;7(3):149-9
39. Kelly DL, Richardson CM, Tamminga CA, Carpenter WT. The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: A double-blind, crossover study. J Clin Psychopharmacol 2003;23(6):668-70
40. Essali A, Al-Haj HN, Li C, Rathbone J. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev 2009;(1):CD000059
41. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis. The Lancet 2013;382(9896):951-62
42. Meltzer H, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophreniainternational suicide prevention trial (InterSePT). Arch Gen Psychiatry 2003;60(1):82-91
43. Tiihonen J, Lonnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: A population-based cohort study (FIN11 study). Lancet 2009; 374(9690):620-7
44. Mustafa FA, Burke JG, Abukmeil SS, et al. "Schizophrenia past Clozapine": Reasons for Clozapine Discontinuation, Mortality, and Alternative Antipsychotic Prescribing. Pharamacopsychiatry 2015;48:11-14
45. Fink M. Rediscovering catatonia: the biography of a treatable syndrome. Acta Psychiatr Scand Suppl 2013;127(s441):1-47
46. d-Elia G. Unilateral electroconvulsive therapy. Acta Psychiatrica Scand Supplementum 1970;215:1-98
47. Petrides G, Malur C, Braga RJ, et al. Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: A prospective, randomized study. Am J Psychiatry 2014;172(1):52-8
48. Kristensen D, Hagemann I, Bauer J, et al. Antipsychotic polypharmacy in a treatment-refractory schizophrenia population receiving adjunctive treatment with electroconvulsive therapy. J ECT 2013; 29(4):271-6
49. Demjaha A, Egerton A, Murray RM, et al. Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. Biol Psychiatry 2014;75(5):e11-13
50. Zink M. Plasticity of brain development as a perspective of basic science in psychiatry. Shaker Verlag-Online Publication 2007
51. Stan A, Lewis D. Altered Cortical GABA neurotransmission in schizophrenia: insights into novel therapeutic strategies. Curr Pharm Biotechnol 2012;13(8):1557-62
52. Byne W, Davis KL. The role of prefrontal cortex in the dopaminergic dysregulation of schizophrenia. Biol Psychiatry 1999;45: 657-9
53. Kapur S. Psychosis as a state of aberrant salience: A framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry 2003; 160(1):13-23
54. Correll CU. Mechanism of action of antipsychotic medications. J Clin Psychiatry 2014;75(9):e23
55. Han M, Huang XF, Deng C. Aripiprazole differentially affects mesolimbic and nigrostriatal dopaminergic transmission: implications for long-term drug efficacy and low extrapyramidal side-effects. Int J Neuropsychopharmacol 2009;12(7):941-52
56. Maeda K, Lerdrup L, Sugino H, et al. Brexpiprazole II: Antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther 2014;350(3):605-14
57. Maeda K, Sugino H, Akazawa H, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther 2014;350(3):589-604
58. Kane JM, Skuban A, Ouyang J, et al. A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophr Res 2015. [Epub ahead of print]
59. Englisch S, Morgen K, Meyer-Lindenberg A , Zink M. Risks and benefits of Bupropion treatment in Schizophrenia: A systematic review of the current literature. Clin Neuropharmacol 2013;36(6):203-15
60. Englisch S, Esser A, Zink M. Bupropion for Depression in Schizophrenia: A case report. Pharmacopsychiatry 2010;43:38-9
61. Lopez-Gil X, Artigas F, Adell A. Unraveling monoamine receptors involved in the action of typical and atypical antipsychotics on glutamatergic and serotonergic transmission in prefrontal cortex. Curr Pharm Des 2010; 16(5):502-15
62. Meyer G, Schaaps JP, Moreau L, Goffinet AM. Embryonic and early fetal development of the human neocortex. J Neurosci 2000;20(5):1858-68
63. Behar TN, Scott CA, Greene CL, et al. Glutamate acting at NMDA receptors stimulates embryonic cortical neuronal migration. J Neurosci 1999;19(11):4449-61
64. Haydar TF, Wang F, Schwartz ML, Rakic P. Differential modulation of proliferation in the Neocortical ventricular and subventricular zones. J Neurosci 2000; 20(15):5764-74
65. Zink M, Englisch S, Schmitt A. Antipsychotic treatment modulates glutamate transport and NMDA receptor expression. Eur Archives Psychiatry Clin Neurosci 2014;264(Suppl 1):S67-82
66. Danbolt NC. Glutamate uptake. Prog Neurobiol 2001;65(1):1-105
67. Bale TL, Baram TZ, Brown AS, et al. Early Life Programming and Neurodevelopmental Disorders. Biol Psychiatry 2010;68(4): 314-19
68. Insel TR. Rethinking schizophrenia. Nature 2010;468(7321):187-93
69. Zilles K, Amunts K. Receptor mapping: Architecture of the human cerebral cortex. Miscellaneous Article Curr Opin Neurol 2009;22(4):331-9
70. Willner P, Mitchell PJ. The validity of animal models of predisposition to depression. Behav Pharmacol 2002;13(3): 169-88
71. Inta D, Monyer H, Sprengel R, et al. Mice with genetically altered glutamate receptors as models of schizophrenia: A comprehensive review. Neurosci Biobehav Rev 2010;34(3): 285-94
72. Segnitz N, Ferbert T, Schmitt A, et al. Effects of chronic oral treatment with aripiprazole on the expression of NMDA receptor subunits and binding sites in rat brain. Psychopharmacology (Berl) 2011;217(1):127-42
73. Espinosa JS, Wheeler DG, Tsien RW, Luo L. Uncoupling dendrite growth and patterning: single-cell knockout analysis of NMDA Receptor 2B. Neuron 2009;62: 205-17
74. Gielen M, Retchless BS, Mony L, et al. Mechanism of differential control of NMDA receptor activity by NR2 subunits. Nature 2009;459:703-7
75. Fuente-Sandoval C, León-Ortiz P, Azcárraga M, et al. Glutamate levels in the associative striatum before and after 4 weeks of antipsychotic treatment in first-episode psychosis: A longitudinal proton magnetic resonance spectroscopy study. JAMA Psychiatry 2013;70(10):1057-66
76. Citrome L. Adding lithium or anticonvulsants to antipsychotics for the treatment of schizophrenia: useful strategy or exercise in futility? J Clin Psychiatry 2009;70(6):932-3
77. Leucht S, Kissling W, McGrath J. Lithium for schizophrenia. Cochrane Database Syst Rev 2007(3):CD003834
78. Leucht S, Kissling W, McGrath J, White P. Carbamazepine for schizophrenia. Cochrane Database Syst Rev 2007(3):CD001258
79. Casey DE, Daniel DG, Tamminga C, et al. Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia. Neuropsychopharmacology 2009;34(5): 1330-8
80. Schwarz C, Volz A, Li C, Leucht S. Valproate for schizophrenia. Cochrane Database Syst Rev 2008(3):CD004028
81. Nakato Y, Abekawa T, Inoue T, Koyama T. Lamotrigine blocks repeated high-dose methamphetamine-induced behavioral sensitization to dizocilpine (MK-801), but not methamphetamine in rats. Neurosci Lett 2011;504(2):131-4
82. Anand A, Charney DS, Oren DA, et al. Attenuation of the neuropsychiatric effects of ketamine with lamotriginesupport for hyperglutamatergic effects of N-methyl-Daspartate Receptor Antagonists. Arch Gen Psychiatry 2000;57(3):270-6
83. Papazisis G, Kallaras K, Kaiki-Astara A, et al. Neuroprotection by lamotrigine in a rat model of neonatal hypoxic-ischaemic encephalopathy. Int J Neuropsychopharmacol 2008;11(3):321-9
84. Williams HJ, Zamzow CR, Robertson H, Dursun SM. Effects of clozapine plus lamotrigine on phencyclidine-induced hyperactivity. Progress in Neuro-Psychopharmacol Biol Psychiatry 2006;30(2):239-43
85. Tiihonen J, Wahlbeck K, Kiviniemi V. The efficacy of lamotrigine in clozapine-resistant schizophrenia: A systematic review and meta-analysis. Schizophr Res 2009;109(1-3): 10-14
86. Zoccali R, Muscatello MR, Bruno A, et al. The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: A double-blind, placebo-controlled study. Schizophr Res 2007;93(1-3):109-16
87. Veerman SRT, Schlulte PFJ, Begemann MJH, et al. Clozapine augmented with glutamate modulators in refractory schizophrenia: A review and metaanalysis. Pharmacopsychiatry 2014;47: 185-94
88. Tiihonen J, Hallikainen T, Ryynänen O-P, et al. lamotrigine in treatment-resistant schizophrenia: A randomized placebo-controlled crossover trial. Biol Psychiatry 2003;54:1241-8
89. Sommer IE, Begemann MJH, Temmerman A, Leucht S. pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: A quantitative literature review. Schizophr Bull 2012;38(5):1003-11
90. Nielsen J, Damkier P, Lublin H, Taylor D. Optimizing clozapine treatment. Acta Psychiatr Scand 2011;123(6):411-22
91. Glick ID, Bosch J, Casey DE. A double-blind randomized trial of mood stabilizer augmentation using lamotrigine and valproate for patients with schizophrenia who are stabilized and partially responsive. J Clin Psychopharmacol 2009;29(3):267-71
92. De Haan L, Schirmbeck F, Zink M, editors. Obsessive-Compulsive Symptoms in Schizophrenia. Springer Cham Heidelberg, New York Dordrecht London; 2015
93. Deutsch SI, Rosse RB, Billingslea EN, et al. Topiramate antagonizes MK-801 in an animal model of schizophrenia. Eur J Pharmacol 2002;449(1-2):121-5
94. Frau R, Orru M, Fa M, et al. Effects of Topiramate on the Prepulse Inhibition of the Acoustic Startle in Rats. Neuropsychopharmacology 2006;32(2): 320-31
95. Jardemark KE, Konradsson A, Schilström BÂ., et al. Differential effects of topiramate on prefrontal glutamatergic transmission when combined with raclopride or clozapine. Synapse 2009; 63(10):913-20
96. Dursun SM, Deakin JF. Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: A naturalistic case-series outcome study. J Psychopharmacol 2001;15(4):297-301
97. Afshar H, Roohafza H, Mousavi G, et al. Topiramate add-on treatment in schizophrenia: A randomised, double-blind, placebo-controlled clinical trial. J Psychopharmacol 2009;23(2):157-62
98. Hahn MK, Remington G, Bois D, Cohn T. Topiramate augmentation in clozapine-treated patients with schizophrenia: clinical and metabolic effects. J Clin Psychopharmacol 2010;30(6):706-10
99. Muscatello MR, Bruno A, Pandolfo G, et al. Topiramate augmentation of clozapine in schizophrenia: A double-blind, placebo-controlled study. J Psychopharmacol 2011;25(5):667-74
100. Vieta E, Sanchez-Moreno J, Goikolea JM, et al. Effects on weight and outcome of long-term olanzapine-topiramate combination treatment in bipolar disorder. J Clin Psychopharmacol 2004;24(4):374-8
101. Hahn MK, Cohn T, Teo C, Remington G. Topiramate in schizophrenia: A review of effects on psychopathology and metabolic parameters. Clin Schizophr Relat Psychoses 2013;6(4):186-96
102. Siok CJ, Taylor CP, Hajos M. Anxiolytic profile of pregabalin on elicited hippocampal theta oscillation. Neuropharmacology 2009;56(2):379-85
103. Tassone DM, Boyce E, Guyer J, et al. Pregabalin: A novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin Ther 2007;29(1): 26-48
104. Bandelow B, Wedekind D, Leon T, et al. Pregabalin for the treatment of generalized anxiety disorder: A novel pharmacologic intervention. Expert Rev Neurother 2007; 7(7):769-81
105. Nunes EA, Canever L, Oliveira L, et al. Effects of pregabalin on behavioral alterations induced by ketamine in rats. Revista Brasileira de Psiquiatria 2012;34(3): 329-33
106. Acheson DT, Stein MB, Paulus MP, et al. The effect of pregabalin on sensorimotor gating in 'low' gating humans and mice. Neuropharmacology 2015;63(3):480-5
107. Schonfeldt-Lecuona C, Wolf RC, Osterfeld ND, et al. Pregabalin in the treatment of schizophrenic anxiety. Pharmacopsychiatry 2009;42(3):124-5
108. Englisch S, Esser A, Enning F, et al. Augmentation with pregabalin in schizophrenia. J Clin Psychopharmacol 2010;30(4):437-40
109. Garay RP, Samalin L, Hameg A, Llorca PM. Investigational drugs for anxiety in patients with schizophrenia. Expe Opin Investig Drugs 2015;24(4):507-17
110. Englisch S, Alm B, Meyer-Lindenberg A, Zink M. Pregabalin-associated increase of clozapine serum levels. J Clin Psychopharmacol 2012;32(1):127-7
111. Hashimoto K, Malchow B, Falkai P, Schmitt A. Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur Arch Psychiatry Clin Neurosci 2013;263(5):367-77
112. Papanastasiou E, Stone JM, Shergill S. When the drugs do not work: the potential of glutamatergic antipsychotics in schizophrenia. Br J Psychiatry 2013;202(2): 91-3
113. Ohnuma T, Tessler S, Arai H, et al. Gene expression of metabotropic glutamate receptor 5 and excitatory amino acid transporter 2 in the schizophrenic hippocampus. Mol Brain Res 2000;85(1-2): 24-31
114. Kinney GG, Burno M, Campbell UC, et al. Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents. J Pharmacol Exper Ther 2003;306(1):116-23
115. Tan HY, Chen Q, Sust S, et al. Epistasis between catechol-O-methyltransferase and type II metabotropic glutamate receptor 3 genes on working memory brain function. Proc Natl Acad Sci USA 2007;104(30): 12536-41
116. Wieronska JM, Slawinska A, Stachowicz K, et al. The reversal of cognitive, but not negative or positive symptoms of schizophrenia, by the mGlu2/3 receptor agonist, LY379268, is 5-HT1A dependent. Behav Brain Res 2013;256(0):298-304
117. Horiguchi M, Huang M, Meltzer H. Interaction of mGlu2/3 agonism with clozapine and lurasidone to restore novel object recognition in subchronic phencyclidine-treated rats. Psychopharmacology (Berl) 2011;217(1): 13-24
118. Chavez-Noriega LE, Schaffhauser H, Campbell UC. Metabotropic glutamate receptors: potential drug targets for the treatment of schizophrenia. Current Drug Targets CNS Neurol Disord 2002;1(3): 261-81
119. Matosin N, Newell KA. Metabotropic glutamate receptor 5 in the pathology and treatment of schizophrenia. Neurosci Biobehav Rev 2013;37(3):256-68
120. Patil ST, Zhang L, Martenyi F, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized Phase 2 clinical trial. Nat Med 2007;13(9):1102-7
121. Stauffer VL, Millen BA, Andersen S, et al. Pomaglumetad methionil: No significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo. Schizophr Res 2013;150(2-3):434-41
122. Kinon BJ, Zhang L, Millen BA, et al. A multicenter, inpatient, phase 2, double-blind, placebo-controlled doseranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J Clin Psychopharmacol 2011;31(3):349-55
123. Clinicaltrials.gov. Available from: www. clinicaltrials.gov
124. Nunes EA, MacKenzie EM, Rossolatos D, et al. D-serine and schizophrenia: An update. Expert Rev Neurother 2012; 12(7):801-12
125. Tsai GE, Lin PY. Strategies to enhance Nmethyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Curr Pharm Des 2010;16(5):522-37
126. Singh S, Singh V. Meta-Analysis of the Efficacy of Adjunctive NMDA Receptor Modulators in Chronic Schizophrenia. CNS Drugs; 2011;25(10):859-85
127. Gadea A, Lopez-Colome AM. Glial transporters for glutamate, glycine, and GABA III. Glycine transporters. J Neurosci Res 2001;64(3):218-22
128. Tsai G, Ralph-Williams RJ, Martina M, et al. Gene knockout of glycine transporter 1: characterization of the behavioral phenotype. Proc Natl Acad Sci USA 2004; 101(22):8485-90
129. Yee BK, Balic E, Singer P, et al. Disruption of glycine transporter 1 restricted to forebrain neurons is associated with a procognitive and antipsychotic phenotypic profile. J Neurosci 2006;26(12):3169-81
130. Jardemark K, Marcus M, Malmerfelt A, et al. Differential effects of AMPA receptor potentiators and glycine reuptake inhibitors on antipsychotic efficacy and prefrontal glutamatergic transmission. Psychopharmacology (Berl) 2012;221(1): 115-31
131. Nikiforuk A, Kos T, Rafa D, et al. Blockade of glycine transporter 1 by SSR-504734 promotes cognitive flexibility in glycine/NMDA receptor-dependent manner. Neuropharmacology 2011;61(1-2): 262-7
132. Burnet PWJ, Hutchinson L, von Hesling M , et al. Expression of D-serine and glycine transporters in the prefrontal cortex and cerebellum in schizophrenia. Schizophr Res 2008;102(1-3):283-94
133. Tsai SJ, Cheng CY, Hong CJ, et al. Association study of polymorphisms in glycine transporter with schizophrenia. J Neural Transm 2006;113(10):1545-9
134. D'Souza DC, Singh N, Elander J, et al. Glycine Transporter Inhibitor Attenuates the Psychotomimetic Effects of Ketamine in Healthy Males: Preliminary Evidence. Neuropsychopharmacology 2012;37(4): 1036-46
135. Liem-Moolenaar M, Zoethout RWM, de Boer P, et al. The effects of the glycine reuptake inhibitor R213129 on the central nervous system and on scopolamine-induced impairments in psychomotor and cognitive function in healthy subjects. J Psychopharmacol 2010;24(11):1671-9
136. Sur C, Kinney GG. The therapeutic potential of glycine transporter-1 inhibitors. Expert Opin Investig Drugs 2004;13(5): 515-21
137. Millan MJ. N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives. Psychopharmacology (Berl) 2005;179(1):30-53
138. Yang CR, Svensson KA. Allosteric modulation of NMDA receptor via elevation of brain glycine and D-serine: the therapeutic potentials for schizophrenia. Pharmacol Ther 2008;120(3):317-32
139. Shim SS, Hammonds MD, Kee BS. Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site. Eur Archives Psychiatry Clin Neurosci 2008;258(1):16-27
140. Patel DD, Laws KR, Padhi A, et al. The neuropsychology of the schizo-obsessive subtype of schizophrenia: A new analysis. Psychol Med 2010;40(6):921-33
141. Umbricht D, Alberati D, Martin-Facklam M. Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: A randomized, double-blind, proof-of-concept study. JAMA Psychiatry 2014;71(6):637-46
142. Bugarski-Kirola D, Wang A, Abi-Saab D, Blüttler T. A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia-Results from the CandleLyte study. Eur Neuropsychopharmacol 2014;24(7):1024-36
143. Roche. Available from: www.roche.com/ media/mediáreleases/med-cor-2014-01-21. htm
144. Roche. Available from: www.roche.com/ irp101209.pdf
145. Harsing LG, Timar J, Szabo G, et al. Sarcosine-based glycine transporter type-1 (GlyT-1) inhibitors containing pyridazine moiety: A further search for drugs with potential to influence schizophrenia negative symptoms. Curr Pharm Des 2015. [Epub ahead of print]
146. Miyaoka T, Yasukawa R, Yasuda H, et al. Minocycline as adjunctive therapy for schizophrenia: An open-label study. Clin Neuropharmacol 2008;31(5):287-92
147. Miyaoka T. Clinical potential of minocycline for schizophrenia. CNS Neurol Disorders Drug Targets 2008;7(4):376-81
148. Levkovitz Y, Mendlovich S, Riwkes S, et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry 2010;71(2): 138-49
149. Oya K, Kishi T, Iwata N. Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: A systematic review and meta-analysis of randomized controlled trials. Hum Psychopharmacol 2014;29(5): 483-91
150. Addex. Available from: www. Addextherapeutics.com/investors/pressreleases/ news-details/article/addex-reportstopline-data-from-a-successful-phase-2aclinicalstudy-with-adx71149-inschizophrenia
151. Krivoy A, Weizman A, Laor L, et al. Addition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: A preliminary study. Eur Neuropsychopharmacol 2008;18(2): 117-21
152. Lieberman JA, Papadakis K, Csernansky J, et al. A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia. Neuropsychopharmacology 2009;34(5): 1322-9
153. Lin CH, Lane HY, Tsai GE. Glutamate signaling in the pathophysiology and therapy of schizophrenia. Pharmacol Biochem Behav 2012;100(4):665-77
154. Pirotte B, Francotte P, Goffin E, de Tullio P. AMPA receptor positive allosteric modulators: A patent review. Expert Opin Ther Patents 2013;23(5): 615-28
155. Wiedholz LM, Owens WA, Horton RE, et al. Mice lacking the AMPA GluR1 receptor exhibit striatal hyperdopaminergia and 'schizophrenia-related' behaviors. Mol Psychiatry 2008;13(6):631-40
156. Goff DC, Leahy L, Berman I, et al. A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. J Clin Psychopharmacol 2001;21(5):484-7
157. Goff DC, Lamberti JS, Leon AC, et al. A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacology 2008;33(3):465-72
158. Chiusaroli R, Garofalo P, Espinoza S, et al. Antipsychotic-like effects of the N-methyl-daspartate receptor modulator neboglamine: An immunohistochemical and behavioural study in the rat. Pharmacol Res 2010;61(5): 430-6
159. Cabungcal JH, Counotte D-A, Lewis EM, et al. Juvenile antioxidant treatment prevents adult deficits in a developmental model of schizophrenia. Neuron. 2014; 83(5):1073-84
160. Moeller M, Du Preez J, Viljoen F, et al. N-acetyl cysteine reverses social isolation rearing induced changes in cortico-striatal monoamines in rats. Metab Brain Dis 2013; 28(4):687-96
161. Moeller M, Du Preez JL, Viljoen FP, et al. Social isolation rearing induces mitochondrial, immunological, neurochemical and behavioural deficits in rats, and is reversed by clozapine or N-acetyl cysteine. Brain Beha Immun 2013; 30(0):156-67
162. Carmeli C, Knyazeva MG, Cünod M, Do KQ. Glutathione Precursor N-Acetyl-Cysteine Modulates EEG synchronization in schizophrenia patients: A double-blind, randomized, placebo-controlled trial. PLoS One 2012; 7(2):e29341
163. Lavoie S, Murray MM, Deppen P, et al. Glutathione Precursor, N-Acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology 2007;33(9): 2187-99
164. Berk M, Copolov D, Dean O, et al. N-Acetyl cysteine as a glutathione precursor for schizophrenia-A double-blind, randomized, placebo-controlled trial. Biol Psychiatry 2008;64(5):361-8
165. Nitta M, Kishimoto T, Mueller N, et al. Adjunctive Use of Nonsteroidal Anti-inflammatory Drugs for Schizophrenia: A Meta-analytic Investigation of Randomized Controlled Trials. Schizophr Bull 2013;39(6):1230-41
166. Rapado-Castro M, Berk M, Venugopal K, et al. Towards stage specific treatments: Effects of duration of illness on therapeutic response to adjunctive treatment with N-acetyl cysteine in schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry 2015;57(0):69-75
167. Woods SW, Walsh BC, Hawkins KA, et al. Glycine treatment of the risk syndrome for psychosis: Report of two pilot studies. Eur Neuropsychopharmacol 2013;23(8):931-40
168. Svenningsson P, Nairn AC, Greengard P. DARPP-32 mediates the actions of multiple drugs of abuse. AAPS J 2005;7(2):E353-60
169. Konradi C, Cole RL, Heckers S, Hyman SE . Amphetamine regulates gene expression in rat striatum via transcription factor CREB. J Neurosci 1994;14(9):5623-34
170. Fusar-Poli P, Borgwardt S, Bechdolf A, et al. The psychosis high-risk state: A comprehensive state-of-the-art review. JAMA Psychiatry 2013;70(1):107-20
171. Correll CU, Hauser M, Auther AM, Cornblatt BA. Research in people with psychosis risk syndrome: A review of the current evidence and future directions. J Child Psychol Psychiatry 2010;51(4): 390-431
172. Yoshimi N, Fujita Y, Ohgi Y, et al. Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: A role for serotonin 5-HT1A receptors. Pharmacol Biochem Behave 2014;124:245-9
173. Yoshimi N, Futamura T, Hashimoto K. Improvement of dizocilpine-induced social recognition deficits in mice by brexpiprazole, a novel serotonin-dopamine activity modulator. Eur Neuropsychopharmacol 2015;25(3):356-64
174. Peselmann N, Schmitt A, Gebicke-Haerter P, Zink M. Aripiprazole differentially regulates the expression of Gad67 and ã-amino-butyric acid transporters in rat brain. Eur Arch Psychiatry Clin Neurosci 2013;263(4): 285-97
175. Segnitz N, Schmitt A, Gebicke-Härter P, Zink M. Differential expression of glutamate transporter genes after chronic oral treatment with aripiprazole in rats. Neurochem Int 2009;55(7):619-28
176. Sumiyoshi T, Higuchi Y, Uehara T. Neural Basis for the Ability of Atypical Antipsychotic Drugs to Improve Cognition in Schizophrenia. Frontiers in Behav Neurosci 2013;7:140
177. Sumiyoshi T, Higuchi Y. Facilitative effect of serotonin(1A) receptor agonists on cognition in patients with schizophrenia. Curr Med Chem 2013;20(3):357-62
178. Meltzer HY, Massey BW. The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr Opin Pharmacol Neurosci 2011;11(1):59-67
179. Correll CU. Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives. Dialogues Clin Neurosci 2011;13(2):155-72
180. Consortium SWGotPG. Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014;511(7510):421-7
181. Ulas J, Nguyen L, Cotman CW. Chronic haloperidol treatment enhances binding to NMDA receptors in rat cortex. Neuroreport 1993;4(8):1049-51
182. Fitzgerald LW, Deutch AY, Gasic G, et al. Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs. J Neurosci 1995; 15(3 Pt 2):2453-61
183. Corbett R, Camacho F, Woods AT, et al. Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors. Psychopharmacology (Berl) 1995;120(1): 67-74
184. Schmitt A, Zink M, Mueller B, et al. Effects of long-term antipsychotic treatment on NMDA receptor binding and gene expression of subunits. Neurochem Res 2003;28(2):235-41
185. Cosi C, Waget A, Rollet K, et al. Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation. Brain Res 2005;1043(1-2):32-41
186. Bruins Slot LA, Kleven MS, Newman-Tancredi A. Effects of novel antipsychotics with mixed D(2) antagonist/ 5-HT(1A) agonist properties on PCP-induced social interaction deficits in the rat. Neuropharmacology 2005;49(7): 996-1006
187. Fejgin K, Safonov S, Palsson E, et al. The atypical antipsychotic, aripiprazole, blocks phencyclidine-induced disruption of prepulse inhibition in mice. Psychopharmacology (Berl) 2007;191: 377-85
188. Leite JV, Guimaraes FS, Moreira FA. Aripiprazole, an atypical antipsychotic, prevents the motor hyperactivity induced by psychotomimetics and psychostimulants in mice. Eur J Pharmacol 2008;578(2-3):222-7
189. Nordquist RE, Risterucci C, Moreau JL, et al. Effects of aripiprazole/OPC-14597 on motor activity, pharmacological models of psychosis, and brain activity in rats. Neuropharmacology 2008;54(2):405-16
190. Snigdha S, Neill JC. Improvement of phencyclidine-induced social behaviour deficits in rats: involvement of 5-HT1A receptors. Behav Brain Res 2008; 191(1):26-31
191. Kargieman L, Santana N, Mengod G, et al. Antipsychotic drugs reverse the disruption in prefrontal cortex function produced by NMDA receptor blockade with phencyclidine. Proc Natl Acad Sci USA 2007;104(37):14843-8
192. Homayoun H, Moghaddam B. Orbitofrontal cortex neurons as a common target for classic and glutamatergic antipsychotic drugs. Proc Natil Acad Sci USA 2008;105(46):18041-6
193. McLean SL, Idris NF, Woolley ML, Neill JC. D1-like receptor activation improves PCP-induced cognitive deficits in animal models: Implications for mechanisms of improved cognitive function in schizophrenia. Eur Neuropsychopharmacol 2009;19(6):440-50
194. Choi YK, Gardner MP, Tarazi FI. Effects of risperidone on glutamate receptor subtypes in developing rat brain. Eur Neuropsychopharmacol 2009;19(2):77-84
195. Tarazi FI, Choi YK, Gardner M, et al. Asenapine exerts distinctive regional effects on ionotropic glutamate receptor subtypes in rat brain. Synapse 2009;63(5):413-20
196. Nagai T, Murai R, Matsui K, et al. Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors. Psychopharmacology (Berl) 2009;202(1-3): 315-28
197. Seibt KJ, Oliveira Rda L, Zimmermann FF, et al. Antipsychotic drugs prevent the motor hyperactivity induced by psychotomimetic MK-801 in zebrafish (Danio rerio). Behav Brain Res 2010;214(2):417-22
198. Carli M, Calcagno E, Mainini E, et al. Sertindole restores attentional performance and suppresses glutamate release induced by the NMDA receptor antagonist CPP. Psychopharmacology (Berl) 2011;214(3): 625-37
199. Zangrando J, Carvalheira R, Labbate G, et al. Atypical antipsychotic olanzapine reversed deficit on prepulse inhibition of the acoustic startle reflex produced by microinjection of dizocilpine (MK-801) into the inferior colliculus in rats. Behav Brain Res 2013;257(0):77-82
200. Huang M, Panos JJ, Kwon S, et al. Comparative effect of lurasidone and blonanserin on cortical glutamate, dopamine, and acetylcholine efflux: role of relative serotonin (5-HT)2A and DA D2 antagonism and 5-HT1A partial agonism. J Neurochem 2014;128(6):938-49
201. Zhang C, Fang Y, Xu L. Glutamate receptor 1 phosphorylation at serine 845 contributes to the therapeutic effect of olanzapine on schizophrenia-like cognitive impairments. Schizophr Res 2014;159(2-3): 376-84